Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Trial Profile

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2019

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Jun 2019 Results assessing safety and clinical activity in the non-small cell lung cancer cohort published in the Journal of Thoracic Oncology.
    • 04 Jun 2019 Results assessing molecular circulating tumor DNA response to identify long-term survival from NCT01693562, NCT02087423 and NCT02261220 trials presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2019 Results assessing longitudinal tumor size and neutrophil to lymphocyte ratio from NCT02087423 and NCT01693562, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top